A de Araújo

Administração Regional de Saúde de Lisboa e Vale do Tejo

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

M. L. Monteiro Cardoso

Centro de Genética Clínica

Guilherme Gonçalves

Administração Regional de Saúde de Lisboa e Vale do Tejo

H. Rodrigues

Fundação Padre Albino

Alinny Rodrigues Lamas

Universidade Federal do Estado do Rio de Janeiro

Carlos Antônio Álvares Soares Ribeiro

Universitario Francisco de Asís

José Ríos

Universitat Autònoma de Barcelona

Idalina Maciel

Administração Regional de Saúde de Lisboa e Vale do Tejo

A Torres

Medical University of Lublin

Armando Meyer

Universidade Federal do Rio de Janeiro

Alexandre H. Kubota

Universidade Federal do Estado do Rio de Janeiro

Cooperative Institutions

Administração Regional de Saúde de Lisboa e Vale do Tejo

Fundação Oswaldo Cruz

Universidade do Porto

Universidade Federal do Estado do Rio de Janeiro

Universidade do Estado do Rio de Janeiro

Escola Nacional de Saúde Pública

Hospital de São João

Universidade Federal do Rio de Janeiro

Humana (United States)

Instituto Gulbenkian de Ciência

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Brote de parotiditis asociado a una baja eficacia de la vacuna - Oporto, Portugal, 1996

Eurosurveillance (1998)

Guilherme Gonçalves A de Araújo M. L. Monteiro Cardoso

En Portugal, la vacunacion contra la parotiditis comenzo en 1987 con la introduccion de la vacuna combinada contra el sarampion, la parotiditis y la rubeola (SPR) en el programa nacional de vacunacion (Programa Nacional de Vacinacao: PNV) para ninos de ambos sexos a los 15 meses de edad. En noviembre de 1990, se anadio al PNV una segunda dosis de SPR a los 11-13 anos de edad. En octubre de 1992, las reacciones adversas atribuidas a la cepa del virus de la parotiditis presente en la vacuna utilizada (Urabe Am9) llevo al Ministerio de Sanidad portugues a reemplazarla por otra vacuna SPR conteniendo la cepa viral Rubini. En octubre de 1992, comenzo a distribuirse en Oporto y en sus centros sanitarios municipales el primer lote de esta ‘nueva’ vacuna.

10.2807/esm.03.12.00101-es

Cite

Citations (0)

Undiagnosed Risk of Obstructive Sleep Apnea in Obese Individuals in a Primary Health Care Context

Acta Médica Portuguesa (2020)

Jaime Pimenta Ribeiro A de Araújo Cláudia Vieira Filipe Vasconcelos Pedro Pinto

Introduction: Obstructive sleep apnea is a clinical entity that is associated with an increase in morbidity and mortality and it is estimated that it is significantly undiagnosed. The objective of this study was to assess the risk of undiagnosed obstructive sleep apneain obese individuals.Material and Methods: A descriptive and analytical cross-sectional study; the risk of obstructive sleep apnea’s was assessed over a period of 11 months by applying the STOP-Bang questionnaire to all individuals who attended a family health unit who were aged ≥ 18 years and had body mass index of ≥ 30 kg/m2 and who had not yet been diagnosed with obstructive sleep apnea and agreed to participate; the risk of an undiagnosed moderate to severe obstructive sleep apnea was considered for any STOP-Bang score of ≥ 3. Results: The risk of undiagnosed obstructive sleep apnea was assessed in 888 individuals (59.3% females) with an average age of 59.6 ± 14.68 years and a mean body mass index 33.6 ± 3.43 kg/m2; the mean STOP-Bang score was 3.5 ± 1.74, 70.9% scored ≥ 3; the frequency of all STOP-Bang questionnaire parameters was higher (p < 0.004) within the group with score ≥ 3.Discussion: The studied population is one of the main strengths, since it is in obese people that the incidence of this disease is higher. There are some limitations related to this sample coming from a single family health unit, as well as the patients’ follow-up being carried out throughout routine appointments for diseases that are closely related with obstructive sleep apnea.Conclusion: The level of underdiagnosis of obstructive sleep apnea’s in obese individuals can be significantly high and a large proportion of them may have the disease at a moderate to severe stage; Family Physicians can have a very important role in screening and diagnosis.

Sleep study

10.20344/amp.12319

Cite

Citations (8)

An integrated evaluation concerning the impact of the use of agro-toxic chemicals on human health within an agricultural community of New Friburg, Rio de Janeiro

Jaime Lima Carla Saturnina Ramos de Moura Sabrina do Carmo Alves M O. Soares Alexandre H. Kubota

Agrochemical

Source

Cite

Citations (0)

Outbreak of mumps associated with poor vaccine efficacy - Oporto Portugal 1996

Eurosurveillance (1998)

Guilherme Gonçalves A de Araújo M. L. Monteiro Cardoso

Vaccination against mumps in Portugal began in 1987, with the introduction of the combined measles, mumps, and rubella vaccine (MMR) in the national vaccination programme (Programa Nacional de Vacinacao: PNV) for both sexes at 15 months. In November 1990,

Measles-Mumps-Rubella Vaccine

MMR vaccine

Rubella vaccine

Mumps vaccine

10.2807/esm.03.12.00101-en

Cite

Citations (38)

485 Evaluation of Oral Hygiene Habits in a Portuguese Primary School Children Population

Pediatric Research (2010)

H. Rodrigues Alinny Rodrigues Lamas Carlos Antônio Álvares Soares Ribeiro A Torres José Ríos

Dental floss

Dental health

Dental plaque

10.1203/00006450-201011001-00485

Cite

Citations (1)

Sindicalismo rural no Acre: contradições em torno do "desenvolvimento sustentável"

Galo Júnior A de Araújo

Source

Cite

Citations (0)

1280 What Parents (Don't) Know About Oral Hygiene…

Pediatric Research (2010)

H. Rodrigues Alinny Rodrigues Lamas José Ríos A Torres Carlos Antônio Álvares Soares Ribeiro

Tooth brushing

10.1203/00006450-201011001-01280

Cite

Citations (0)

Giant Polarization in Quasi‐Adiabatic Ferroelectric Na⁺ Electrolyte for Solid‐State Energy Harvesting and Storage

Advanced Functional Materials (2022)

Manuela C. Baptista Hesham Khalifa A de Araújo Beatriz Arouca Maia Manuel Souto

The advent of new solid‐state energy storage devices to tackle the electrical revolution requires the usage of nonlinear behavior leading to emergent phenomena. The ferroelectric analyzed herein belongs to a family of electrolytes that allow energy harvesting and storage as part of its self‐charging features when thermally activated. The Na 2.99 Ba 0.005 ClO electrolyte shows quasi‐adiabatic behavior with a continuous increase in polarization upon cycling, displaying almost no hysteresis. The maximum polarization obtained at a weak electric field is giant and similar to the remanent polarization. It depends on the temperature with a pyroelectric coefficient of 5.37 C m −2 °C −1 from −5 to 46 °C. The emergence occurs via negative resistance and capacitance. The glass transition is found to have its origins in the sharp depolarization at 46 – 48 °C. Above –10 °C, at ≈ –5 °C, another thermal anomaly may rely on the topologic characteristics of the A 3–2x Ba x ClO (A = Li, Na, K) glass electrolytes enabling positive feedback of the current of electrons throughout the surface of the inner cell. The phenomena may pave the way toward a better understanding of dipolar nanodomain fragile glasses with exceptional ferroelectric characteristics to architect energy harvesting and storage devices based on multivalent thermally activated Na + ‐ion‐ion electrolytes.

10.1002/adfm.202212344

Cite

Citations (5)

Surto de parodidite associado a uma fraca eficácia da vacinação - Porto, Portugal, 1996

Eurosurveillance (1998)

Guilherme Gonçalves A de Araújo M. L. Monteiro Cardoso

A vacinacao contra a parodidite em Portugal teve inicio em 1987, com a introducao da vacina combinada do sarampo, parodidite e rubeola (VASPR) no Programa Nacional de Vacinacao (PNV) para ambos os sexos, aos 15 meses de idade. Em Novembro de 1990, foi adicionada ao PNV uma segunda dose da VASPR, dos 11 aos 13 anos de idade. Em Outubro de 1992, efeitos secundarios atribuidos a estirpe da parodidite (Urabe Am9) levaram o Ministerio da Saude Portugues a substituir a VASPR utilizada em todo o pais por uma VASPR que continha a estirpe Rubini como vacina da parodidite. O primeiro fornecimento da nova vacina chegou ao Porto e foi distribuido pelos centros de saude distritais em Outubro de 1992.

10.2807/esm.03.12.00101-pt

Cite

Citations (0)

Epidémie d’oreillons associée à une faible efficacité vaccinale – Porto, Portugal, 1996

Eurosurveillance (1998)

Gleice Adriana Araújo Gonçalves A de Araújo M. L. Monteiro Cardoso

La vaccination contre les oreillons a debute en 1987 au Portugal avec l’introduction, dans le cadre du Programme national de vaccination (Programa Nacional de Vacinacao : PNV), du vaccin multiple ROR pour les enfants des deux sexes des l’âge de 15 mois. En novembre 1990, une seconde dose de vaccin administree entre 11 et 13 ans a ete ajoutee au PNV. En octobre 1992, a la suite d’effets secondaires attribues a la souche du virus des oreillons Urabe Am9 presente dans le vaccin utilise, le Ministere de la Sante portugais decidait de le remplacer par un vaccin ROR contenant la souche virale Rubini. Le premier stock de ce nouveau vaccin a ete livre a Porto et distribue aux Centres de sante du District en octobre 1992.

10.2807/esm.03.12.00101-fr

Cite

Citations (0)